Cancer Research 09 AM Call for Abstracts  SU2C
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 46, 4053-4057, August 1, 1986]
© 1986 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marsh, W.
Right arrow Articles by Center, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marsh, W.
Right arrow Articles by Center, M. S.

Isolation and Characterization of Adriamycin-resistant HL-60 Cells Which Are Not Defective in the Initial Intracellular Accumulation of Drug1

Wallace Marsh, Delores Sicheri and Melvin S. Center2

Division of Biology, Kansas State University, Manhattan, Kansas 66506 [W. M., M. S. C.], and Section of Medical Oncology, Department of Medicine, University of Oklahoma, Health Science Center, Oklahoma City, Oklahoma 73191 [D. S.]

Two human leukemia cell lines (Molt-4 and HL-60) have been used for establishing cells which exhibit a low level resistance to Adriamycin. Analysis of drug uptake patterns shows that the Molt-4 resistant cells are defective in the initial intracellular accumulation of drug. In contrast to Molt-4 the levels of drug which accumulate in the sensitive and resistant HL-60 cells during a 60-min incubation period are essentially the same. However, when incubations are continued there is a major reduction in intracellular drug levels in the resistant cell. Further studies show that resistant cells incubated in the presence of drug for extended time periods efflux drug at a rate considerably greater than that exhibited by the sensitive parent line. Similar efflux patterns are obtained with nuclei isolated from drug-sensitive and -resistant cells. Additional studies using an in vitro phosphorylation system demonstrate distinct protein changes in membranes of Molt-4 and HL-60 resistant cells. Thus, we have found that a membrane fraction from the Molt-4 resistant line contains a Mr 170,000 protein which is not detected in a similar fraction from cells sensitive to drug. HL-60 resistant membranes contain two proteins with molecular weights of 150,000 and 120,000 which are also not found in membranes from drug-sensitive cells. The results of this study suggest that drug resistance in HL-60 cells is related to an efflux mechanism which is triggered only after cells are exposed to drug for prolonged periods.

1 This investigation was supported by Research Grant CA-37585 from the National Cancer Institute, Department of Health and Human Services.

2 To whom requests for reprints should be addressed.

Received 1/ 8/86. Revised 4/18/86. Accepted 4/22/86.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
R. S. Al-awar, T. H. Corbett, J. E. Ray, L. Polin, J. H. Kennedy, M. M. Wagner, and D. C. Williams
Biological evaluation of cryptophycin 52 fragment A analogues: Effect of the multidrug resistance ATP binding cassette transporters on antitumor activity
Mol. Cancer Ther., September 1, 2004; 3(9): 1061 - 1067.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Minderman, K. L. O'Loughlin, L. Pendyala, and M. R. Baer
VX-710 (Biricodar) Increases Drug Retention and Enhances Chemosensitivity in Resistant Cells Overexpressing P-Glycoprotein, Multidrug Resistance Protein, and Breast Cancer Resistance Protein
Clin. Cancer Res., March 1, 2004; 10(5): 1826 - 1834.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. S. McGrath, M. G. Rosenblum, M. R. Philips, and D. A. Scheinberg
Immunotoxin Resistance in Multidrug Resistant Cells
Cancer Res., January 1, 2003; 63(1): 72 - 79.
[Abstract] [Full Text] [PDF]


Home page
INT J SURG PATHOLHome page
K. Toth, M. M. Vaughan, G. Schwartz, J. S. Winston, B. S. Skenderis II, H. K. Slocum, and Y. M. Rustum
Expression of the MRP and MDRI Multidrug Resistance Gene Products in 160 Untreated Human Carcinomas Studied by Immunohistochemical Methods in Formalin-Paraffin Sections
International Journal of Surgical Pathology, July 1, 1998; 6(3): 145 - 154.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
M. Gao, D. W. Loe, C. E. Grant, S. P.C. Cole, and R. G. Deeley
Reconstitution of ATP-dependent Leukotriene C4 Transport by Co-expression of Both Half-molecules of Human Multidrug Resistance Protein in Insect Cells
J. Biol. Chem., November 1, 1996; 271(44): 27782 - 27787.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1986 by the American Association for Cancer Research.